In this study, we identify DNA methylation alterations in MSCs of MM patients mediated by MM cells resulting in the dysregulation of osteogenesis, and this is reversed by the treatment with CM-272, a dual inhibitor of DNMTs and the histone methyltransferase G9a. The gene discussed is PRDM9; the disease is Miyoshi myopathy.